Neuronetics Posts 86% Q4 Revenue Jump, Taps Dan Reuvers as New CEO
STIM sits 28% above its 52-week low of $1.17.
Summary
Neuronetics (STIM) reported robust fourth-quarter and full-year 2025 financial results, with Q4 revenue surging 86% to $41.8 million and full-year revenue up 99% to $149.2 million. The company also achieved positive operating cash flow of $0.9 million in Q4 2025 and provided 2026 revenue guidance of $160 million to $166 million. This comprehensive financial update is new information and not redundant with previous SEC filings. The significant revenue growth was partly driven by the acquisition of Greenbrook TMS Inc. (TCMD), which contributed substantially to clinic revenue. These strong financial results, particularly the high revenue growth rates and positive cash flow, indicate significant operational momentum and improved financial health for Neuronetics. The appointment of Dan Reuvers as the new President and CEO, effective March 23, 2026, is a material executive change, bringing a seasoned medical device leader to guide the company's next phase of growth. Investors will be watching how the new CEO executes on the 2026 revenue guidance and further integrates the Greenbrook acquisition, as well as the progress of collaborations like the one with Compass Pathways.
At the time of this announcement, STIM was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.1M. The 52-week trading range was $1.17 to $5.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.